A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using Gadodiamide
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 395
- Registration Number
- NCT00209391
- Locations
- 🇩🇪
Amersham Buchler GmbH & Co. KG, Ismaning, Germany
Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography
Phase 4
Completed
- Conditions
- Coronary Artery DiseaseRenal Impairment
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-10-31
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 408
- Registration Number
- NCT00209430
- Locations
- 🇸🇪
Amersham Health S.A, Solna, Sweden
Iodixanol in Multidetector-Row Computed Tomography-Coronary Angiography (MDCT-CA)
Phase 4
Completed
- Conditions
- Coronary Artery Disease
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-10-31
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 50
- Registration Number
- NCT00209404
- Locations
- 🇫🇷
Amersham Health S.A., Velizy Cedex, France
Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma
Phase 3
Completed
- Conditions
- PheochromocytomaNeuroblastoma
- Interventions
- Drug: 123I-mIBG (meta-iodobenzylguanidine)
- First Posted Date
- 2005-08-04
- Last Posted Date
- 2019-05-31
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 251
- Registration Number
- NCT00126412
- Locations
- 🇺🇸
GE Healthcare, Princeton, New Jersey, United States
Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
Phase 3
Completed
- Conditions
- Heart Failure, Congestive
- Interventions
- Drug: 123I-mIBG (meta-iodobenzylguanidine)
- First Posted Date
- 2005-08-04
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 587
- Registration Number
- NCT00126425
- Locations
- 🇺🇸
GE Healthcare, Princeton, New Jersey, United States
Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
Phase 3
Completed
- Conditions
- Heart Failure, Congestive
- Interventions
- Drug: 123I-mIBG (meta-iodobenzylguanidine)
- First Posted Date
- 2005-08-04
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 515
- Registration Number
- NCT00126438
- Locations
- 🇺🇸
GE Healthcare, Princeton, New Jersey, United States
© Copyright 2025. All Rights Reserved by MedPath